{
    "clinical_study": {
        "@rank": "126276", 
        "brief_summary": {
            "textblock": "To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in\n      combination with flucytosine, as treatment for acute cryptococcal meningitis."
        }, 
        "brief_title": "Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis", 
        "condition": [
            "Meningitis, Cryptococcal", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Meningitis", 
                "Meningitis, Cryptococcal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Immunosuppressant therapy.\n\n          -  Antiviral such as zidovudine.\n\n          -  Radiation therapy for mucocutaneous Kaposi's sarcoma.\n\n          -  Prophylaxis for Pneumocystis carinii pneumonia (PCP) including aerosol pentamidine.\n\n        Concurrent Treatment:\n\n        Allowed:\n\n          -  Radiation therapy for mucocutaneous Kaposi's sarcoma.\n\n        Written informed consent must be obtained for each patient, either from the patient\n        himself or from the patient's legal guardian.\n\n          -  No prior systemic antifungal therapy for cryptococcosis.\n\n          -  Relapse after prior therapy.\n\n          -  Success of prior therapy must have been documented by negative cerebrospinal fluid\n             (CSF) culture at the end of therapy. Following prior therapy, such patients may not\n             have received more than 1 mg/kg/wk amphotericin B in the 4 weeks before entry into\n             study.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Immunosuppressant therapy.\n\n          -  Antivirals such as zidovudine (AZT).\n\n          -  Prophylaxis for Pneumocystis carinii pneumonia (PCP) including aerosol pentamidine.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Evidence of acute or chronic meningitis based upon any etiology other than\n             cryptococcosis.\n\n          -  History of allergy to or intolerance of imidazoles, azoles, or amphotericin B.\n\n          -  Moderate or severe liver disease.\n\n          -  Comatose.\n\n          -  Unlikely to survive more than 2 weeks.\n\n          -  Any exceptions to these prohibitions of concomitant medications must be approved by\n             Pfizer Central Research.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Coumadin-type anticoagulants.\n\n          -  Oral hypoglycemics.\n\n          -  Barbiturates.\n\n          -  Phenytoin.\n\n          -  Immunostimulants.\n\n          -  Investigational drugs or approved (licensed) drugs for investigational indications.\n\n          -  Any exceptions to these prohibitions of concomitant medications must be approved by\n             Pfizer Central Research.\n\n          -  Excluded within 4 weeks of study entry:\n\n          -  Received more than 1 mg/kg/wk amphotericin B.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Lymphocyte replacement.\n\n        Patients with the following are excluded:\n\n          -  Evidence of acute or chronic meningitis based upon any etiology other than\n             cryptococcosis.\n\n          -  History of allergy to or intolerance of imidazoles, azoles, or amphotericin B.\n\n          -  Moderate or severe liver disease.\n\n          -  Comatose.\n\n          -  Unlikely to survive more than 2 weeks.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Coumadin-type anticoagulants.\n\n          -  Oral hypoglycemics.\n\n          -  Barbiturates.\n\n          -  Phenytoin.\n\n          -  Immunostimulants.\n\n          -  Investigational drugs or approved (licensed) drugs for investigational indications.\n\n          -  Excluded within 4 weeks of study entry:\n\n          -  More than 1 mg/kg/wk amphotericin B.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Lymphocyte replacement."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002075", 
            "org_study_id": "012G", 
            "secondary_id": "056-159A"
        }, 
        "intervention": [
            {
                "intervention_name": "Flucytosine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Fluconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Amphotericin B", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amphotericin B", 
                "Liposomal amphotericin B", 
                "Fluconazole", 
                "Flucytosine"
            ]
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Meningitis", 
            "Cryptococcosis", 
            "Drug Therapy, Combination", 
            "Fluconazole", 
            "Flucytosine", 
            "Acquired Immunodeficiency Syndrome", 
            "Amphotericin B"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90033"
                }, 
                "name": "Dr Robert Larsen"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002075"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 1989"
    }, 
    "geocoordinates": {
        "Dr Robert Larsen": "34.052 -118.244"
    }
}